[HTML][HTML] A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - Medicine, 2022 - journals.lww.com
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - …, 2022 - scholarworks.bwise.kr
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, alpha-galactosidase A (alpha-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, alpha-galactosidase A (alpha-Gal A), which leads to globotriaosylceramide (Gb3) …
A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, B Lee, W Kim, D Kim, C Cheon, C Lee… - Medicine, 2022 - europepmc.org
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim… - Medicine (United …, 2022 - khu.elsevierpure.com
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
[HTML][HTML] A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - Medicine, 2022 - ncbi.nlm.nih.gov
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
[HTML][HTML] A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - Medicine, 2022 - journals.lww.com
Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …
A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - Medicine, 2022 - europepmc.org
Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal enzyme, α-
galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) deposition in multiple …
galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) deposition in multiple …